Abstract: The present the invention relates to a new use of retinoic of hyaluronic acid, that exhibit pre-differentiating activity on totipotent stem cells. The invention also relates to a process to differentiate said stem cells and to select molecules capable of modulating the pro-differentiating activity of those esters.

Abstract: The present invention relates to mixed esters of hyaluronic acid, wherein the hydroxyl groups are partially esterified with retinoic and butyric acids. These mixed esters are characterized by specific degrees of esterification and by a high ratio between the degree of substitution with butyric acid and retinoic acid. They exhibit a high anti-proliferative activity associated with activation of cell differentiation, with consequent clinical relevance in the treatment of hyper-proliferative pathologies and in particular of solid and systemic tumors.

Abstract: The present invention relates to polysaccharidic esters of retinoic acid, wherein the hydroxyl groups of the monosaccharidic units of the polysaccharide are partially or totally esterified with retinoic acid. A process to obtain these esters is also described. The products according to the present invention can be used in the pharmaceutical and cosmetic field.

Abstract: The present invention relates to polysaccharidic esters of retinoic acid, wherein the hydroxyl groups of the monosaccharidic units of the polysaccharide are partially or totally esterified with retinoic acid. A process to obtain these esters is also described. The products according to the present invention can be used in the pharmaceutical and cosmetic field.

Abstract: The present application describes total or partial butyric esters of polysaccharides as novel compounds; the number of hydroxyl groups esterified with butyric residues per each glycosidic monomer is preferably higher than 0.001; the application also describes the process of preparation of said esters, their use in therapy as antiproliferative agents, and pharmaceutical compositions containing them.

Abstract: The present invention relates to a new spongy material consisting essentially of hyaluronic acid or its derivatives. The characteristics of the new pharmaceutical preparations consist in assuring high concentrations of active principle for a long period of time, by exploiting the characteristics of slow release of the active principle.The new pharmaceutical preparations can be utilized advantageously in all the numerous situations of microsurgical practice (in particular the ones relating to ear or in odontostomatology), in which it is necessary to use a substance that can be metabolized by the organism and is capable of making easier flap take, reepithelialization of mucous membranes, stabilization of grafts and filling of cavities.The specific use of the new pharmaceutical preparations is particularly important and useful in the various ear pathologies and in the practice of otologic, otoneurosurgical and odontostomatological microsurgery, such as for instance repair of tympanic perforations.